Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.

MLA

Altan, Mehmet, et al. “Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.” Oncologist, vol. 28, no. 11, Nov. 2023, pp. e1065–74. EBSCOhost, https://doi.org/10.1093/oncolo/oyad118.

APA

Altan, M., Soto, F., Zhong, L. L., Akhmedzhanov, F. O., Wilson, N. R., Zarifa, A., Albittar, A. A., Yang, V., Lewis, J., Rinsurongkawong, W., Jack Lee, J., Rinsurongkawong, V., Zhang, J., Gibbons, D. L., Vaporciyan, A. A., Jennings, K., Khawaja, F., Faiz, S. A., Shannon, V. R., & Shroff, G. (2023). Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist, 28(11), e1065–e1074. https://doi.org/10.1093/oncolo/oyad118

Chicago

Altan, Mehmet, Felipe Soto, Linda L Zhong, Fechukwu O Akhmedzhanov, Nathaniel R Wilson, Abdulrazzak Zarifa, Aya A Albittar, et al. 2023. “Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.” Oncologist 28 (11): e1065–74. doi:10.1093/oncolo/oyad118.